|Videos|July 2, 2013
Episode 17 - Conclusion: Treatment Advancements and Final Remarks
Advertisement
Episodes in this series
During this segment, Patricia K. Coyle, MD, Leslie Fish, PharmD, and Gary M. Owens, MD, explain how research has expanded in the neurology field and discuss the therapeutic pipeline for multiple sclerosis (MS) with Dr Fred Lublin.
Dr Coyle discusses the potential of newly developing agents and explains that clinical trials are now testing the efficacy of these products, which is vital when considering data for future clinical guidelines.
However, Dr Owens suggests that expensive costs of treatment and the lack of clinical recommendations or guidelines can cause confusion to clinicians and challenge the future of MS.
Advertisement
Related to this article
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
Declining serum GFAP during MS treatment was tied to lower PIRA risk, supporting its use as a biomarker for treatment response.
Nearly half of working-age adults were inadequately insured in 2026, and half went without needed care due to cost, a Commonwealth Fund survey found.
AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.
Medicare’s GLP-1 Bridge program aims to expand obesity treatment, but eligibility hurdles and drug costs leave many seniors paying hundreds monthly.
Birth centers are unavailable in 10 states, and 39% of birth center births are self-pay, as licensing and Medicaid pay limit access, a report finds.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
3
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
4
Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts
5